Details
In this analysis, we described counts of new users of long-acting injectable antipsychotics (LAIAs) including paliperidone palmitate, risperidone microspheres, and haloperidol decanoate in the Sentinel Distributed Database (SDD). We estimated the two-week and four-week risk of mortality comparing (1) paliperidone palmitate users to risperidone microspheres users and (2) paliperidone palmitate users to haloperidol decanoate users. As sensitivity analyses, we also evaluated the two-week and four-week risk of mortality among subgroups by age (18-34, 35-44, 45-54, 55-64, 65-74, 75-84, and 85+ years), dementia status (dementia diagnosis and treatment, no dementia diagnosis and treatment), and LAIA administered during an institutional stay (during stay, not during stay).
This analysis is a follow-up to a previous study. In addition to using inverse probability of treatment weighting (IPTW) to adjust for confounding, this follow-up analysis also included continuous age in the outcome regression model to adjust for confounding.
The study period includes data from January 1, 2010 to July 1, 2022. We distributed this request to one Sentinel Data Partner on September 7, 2023.
The analytic package associated with this analysis can be found externally in Sentinel's Git Repository located here. The Git Repository serves as Sentinel's version control tracking system for analytic packages and technical documentation